Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder
Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants (SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from asymptomatic viremia through infectious mononucleosis to posttransplant lymphoproliferative disorder (PTLD). EBV disease and its associated PTLD is more frequently seen when primary EBV infection occurs after transplant, a common scenario in pediatric SOT recipients. Intensity of immunosuppressive therapies also influences the risk for PTLD. The use of EBV viral load monitoring facilitates the diagnosis and management of EBV/PTLD as well as bein...
Source: American Journal of Transplantation - January 24, 2013 Category: Transplant Surgery Authors: M. Green, M. G. Michaels Tags: Continuing Medical Education Source Type: research

Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
Disease OverviewWaldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy. DiagnosisThe presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. Risk StratificationAge, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. Risk‐Adapted TherapyNot all patients who fulfill WM criteria require therapy; these patients can be observe...
Source: American Journal of Hematology - June 20, 2013 Category: Hematology Authors: Morie A. Gertz Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk‐Stratification and Clinical Management
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - June 23, 2015 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Waldenstr öm macroglobulinemia: 2017 update on diagnosis, risk stratification, and management
Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients. Risk Stratification: Age, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. Risk‐Adapt...
Source: American Journal of Hematology - January 16, 2017 Category: Hematology Authors: Morie A. Gertz Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Mantle cell lymphoma: 2017 update on diagnosis, risk ‐stratification, and clinical management
Abstract Disease OverviewMantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4‐5 years. DiagnosisDiagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki...
Source: American Journal of Hematology - July 12, 2017 Category: Hematology Authors: Julie M. Vose Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Source Type: research

Rituximab prevents long-term relapses in TTP
Source: Blood - November 15, 2018 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Theranostics in Hematooncology
In the early 2000s, major clinical trials provided evidence of a favorable outcome from antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food and Drug Administration approval. For instance, the theranostic armamentarium for the referring hematooncologist now includes 90Y-ibritumomab tiuxetan for refractory low-grade follicular lymphoma or transformed B-cell non-Hodgkin lymphoma, as well as 131I-tositumomab for rituximab-refractory follicular lymphoma. Moreover, the first interim results of the SIERRA phase III trial reported beneficial effects from the use of 131I-anti-CD45 antibodies (Ioma...
Source: Journal of Nuclear Medicine - June 30, 2023 Category: Nuclear Medicine Authors: Buck, A. K., Serfling, S. E., Kraus, S., Samnick, S., Dreher, N., Higuchi, T., Rasche, L., Einsele, H., Werner, R. A. Tags: Continuing Education Source Type: research

Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.
CONCLUSION: More evidence regarding the immunogenicity and safety of vaccinations in AIIRD patients under various therapies is needed. Vaccination recommendations should be updated on a regular basis, as more scientific data will become available. PMID: 26218860 [PubMed - in process]
Source: Swiss Medical Weekly - July 31, 2015 Category: Journals (General) Authors: Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, Siegrist CA, Hatz C Tags: Swiss Med Wkly Source Type: research

The evidence for biologic immunotherapy in Sarcoidosis: A systematic review
Conclusion There are insufficient data to suggest the long-term efficacy of anti-TNFα inhibitors in the treatment of sarcoidosis. This may be due to heterogeneity, small sample sizes and the lack of consistent reporting of outcome measures.
Source: Australasian Medical Journal - AMJ - October 4, 2017 Category: General Medicine Source Type: research

Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.
Conclusions: IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED. PMID: 30647961 [PubMed]
Source: Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Autoimmune hemolytic anemia.
Authors: Hill A, Hill QA Abstract The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin test. Once alternative causes for these findings have been excluded, AIHA is established, and the clinician must search for secondary causes, as well as identify the type of AIHA. Rituximab is now the preferred second-line treatment for primary warm AIHA and first-line treatment for primary cold agglutinin disease (CAD), either as monotherapy or com...
Source: Hematology ASH Education Program - December 7, 2018 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
CONCLUSIONS: Encephalitis should be suspected in patients treated with ICIs who present with rapidly evolving confusion. Blood tests, CSF analysis, cerebral MRI and an EEG should be performed. Therapy with intravenous corticosteroids is recommended. Steroid unresponsiveness is rare and should lead to a review of the diagnosis. Alternative treatment options are IVIG, plasma exchange therapy and rituximab. &nbsp. PMID: 33232507 [PubMed - in process]
Source: Swiss Medical Weekly - November 16, 2020 Category: General Medicine Authors: Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A Tags: Swiss Med Wkly Source Type: research

Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions
We describe two patients diagnosed with NMDAR encephalitis presenting with two different psychiatric manifestations.  The first patient presented with psychotic mania and catatonic symptoms, while the second suffered from depression with psychotic and catatonic features refractory to psychotropic medications. We review of the use of psychotropic medications and ECT to address insomnia, agitation, psychosis, mood dysregulation and catatonia in NMDAR encephalitis.
Source: General Hospital Psychiatry - March 6, 2014 Category: Psychiatry Authors: Preetha S. Kuppuswamy, Christopher Robert Takala, Christopher L. Sola Tags: Psychiatric-Medical Comorbidity Source Type: research

Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report
Conclusions A careful search for dermatological manifestations may help with earlier diagnosis. Skin findings may be another marker of endothelial cell involvement. Early use of rituximab as part of the therapeutic regimen may be warranted.
Source: Journal of Medical Case Reports - May 26, 2016 Category: Journals (General) Source Type: research

Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Conclusion: This study provides an accurate assessment of the main lymphoma subtypes related cost with high magnitude of details in a real-world setting. We underline where potential cost saving could be realized via the use of biosimilar medication, and where lymphoma management could be improved with the early management of adverse events.KEY POINTSThis is one of the first studies which assess the additional cost of lymphoma in Europe, according the main sub-types of lymphoma and with real-world database.The additional monthly cost due to HL, FL and DLBCL patients were respectively €5,188, €3,242 and €7,659 for the...
Source: Journal of Medical Economics - December 27, 2019 Category: Health Management Tags: J Med Econ Source Type: research